IL158121A - 5-membered heterocycles, pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments - Google Patents

5-membered heterocycles, pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments

Info

Publication number
IL158121A
IL158121A IL158121A IL15812103A IL158121A IL 158121 A IL158121 A IL 158121A IL 158121 A IL158121 A IL 158121A IL 15812103 A IL15812103 A IL 15812103A IL 158121 A IL158121 A IL 158121A
Authority
IL
Israel
Prior art keywords
butyl
thiazol
methyl
imidazol
ethylcarbamate
Prior art date
Application number
IL158121A
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0104943A external-priority patent/FR2823208B1/en
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of IL158121A publication Critical patent/IL158121A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Claims (1)

1. I l l Claims 1. Compound characterized in that it is chosen from the following compounds: - 2,6-di½ri-butyl-4-{ 2-[2-(methylamino)ethyl]-l,3-thiazol-4-yl}phenol; - 2,6-dite/-/-butyl-4-[4-(hydroxymethyl)-l,3-oxazol-2-yl]phenol; - 2-[l -(methylaniino)ethyl]-l ,3-thiazol-4-yl}phenol; - 2,6-diter -butyl-4-[2-(methoxymethyl)-l,3-thiazol-4-yl]phenol; - 2,6-dite/ -butyl-4-{4-[(methylamino)methyl]-l ,3-oxazol-2-yl }phenol; - N-{ [4-(3,5-dir.?rt-butyl-4-hydroxyphenyl)-l,3-thiazol-2-yl]methyl}acetamide; - ethyl [4-(3,5-diter/-butyl-4-hydroxyphenyl)- 1 ,3-thiazol-2-yl]methylcarbamate; - 2,6-di½r butyl-4-[2-(mo holin-4-ylmethyl)-l,3-thiazol-4-yl]phenol; - 2,6-dirert-butyl-4-[2-(thiomorpholin-4-ylmethyl)-l ,3-thiazol-4-yl]phenol; - 4-[2-(anilinomethyl)-l,3-thiazol-4-yl]-2,6-di½rt-butylphenol; - 2,6-dite/ -butyl-4-(2-{ [[2-(dimethylamino)ethyl](methyl)amino]methyl}-l,3-thiazol-4-yl)phenol; - 2,6-di/e -butyl-4-{5-methyl-2-[(methylamino)methyl]-l,3-thiazol-4-yl}phenol; - l -[4-(10H-phenothiazin-2-yl)-l ,3-thiazol-2-yl]methanamine; - N- { [4-(3,5-di/er -butyl-4-hydroxyphenyl)- 1 ,3-thiazol-2-yl]methyl } -N-methyl acetami de ; - l -[4-(3,5-dir 3. Pharmaceutical composition containing, as active ingredient, at least one of the compounds according to claim 2. 4. Use of a compound characterized in that it is chosen from the following compounds: - 2,6-di/err-butyl-4-{2-[2-(methylamino)ethyl]-l ,3-thiazol-4-yl }phenol; - 2,6-di/err-butyl-4-[4-(hydroxymethyl)-l,3-oxazol-2-yl]phenol; - 2,6-difer/-butyl-4- { 2-[ 1 -(methylamino)ethyl]- 1 ,3-thiazol-4-yl }phenol; - 2,6-di/err-butyl-4-[2-(methoxymethyl)-l,3-thiazol-4-yl]phenol; - 2,6-di/m-butyl-4- { 4- [(methylamino)methyl] - 1 ,3-oxazol-2-yl } phenol ; - N-{ [4-(3,5-di/eri-butyl-4-hydroxyphenyl)-l ,3-thiazol-2-yl]methyl}acetamide; - ethyl [4-(3,5-ditert-butyl-4-hydroxyphenyl)-l,3-thiazol-2-yl]methylcarbamate; - 2,6-di½rr-butyl-4-[2-(morpholin-4-ylmethyl)-l,3-thiazol-4-yl]phenol; - 2,6-di/ert-butyl-4-[2-(thiomo holin-4-ylmethyl)-l,3-thiazol-4-yl]phenol; - 4-[2-(anilinomethyl)-l,3-thiazol-4-yl]-2,6-di½rt-butylphenol; - 2,6-dir -butyl-4-(2-{ [[2-(dimethylarruno)ethyl](methyl)amino]methyl}-l,3-thiazol-4-yl)phenol; - 2,6-direrr-butyl-4-{ 5-methyl-2-[(methylamino)methyl]-l,3-thiazol-4-yl}phenol; - 1 -[4-( 10H-phenothiazin-2-yl)- 1 ,3-thiazol-2-yl]methanamine; - N- { [4-(3,5-direrf-butyl-4-hydroxyphenyl)- 1 ,3-thiazol-2-yl]methyl } -N-methylacetamide; - 1 -[4-(3,5-diterr-butyl-4-methoxyphenyl)- l,3-thiazol-2-yl]-N-methylmethanamine; - 2,6-di/err-butyl-4-{2-[(ethylamino)methyl]-l,3-thiazol-4-yl}phenol; - 2,6-dirm-butyl-4-{ 2-[(4-phenylpiperazin-l -yl)methyl]-l,3-thiazol-4-yl }phenol; - 2,6-dirm-butyl-4- { 2-[(4-methyl- 1 ,4 -diazepan- 1 -yl)methyl]- 1 ,3-thiazol-4-yl Jphenol; - N- { 1 -[4-(4-anilinophenyl)- 1 ,3-thiazol-2-yl]ethyl } -N-methylamine; - 2,6-di½r/-butyl-4-{ 2-[(isopropylamino)methyl]-l,3-thiazol-4-yl}phenol; - 2,6-ditert-butyl-4-{2-[(cyclohexylamino)methyl]-l ,3-thiazol-4-yl}phenol; - 2,6-direrr-butyl-4-{2-[(4-isopropylpiperazin-l-yl)methyl]-l,3-thiazol-4-yl }phenol; - N-methyl-1 -[4-(10H-phenothiazin-2-yl)-l,3-thiazol-2-yl]ethanamine; - 2,6-diri?r/-butyl-4-{2-[(4-ethylpiperazin-l-yl)methyl]-l,3-thiazol-4-yl }phenol; - N-{ [4-(4-anilinophenyl)-l ,3-thiazol-2-yl]methyl}-N-ethylamine; - N-{ [4-(10H-phenothiazin-2-yl)-l ,3-thiazol-2-yl]methyl }ethanamine; - 2,6-direr/-butyl-4-(2- { [4-(dimethylamino)piperidin- 1 -yl]methyl } - 1 ,3-thiazol-4-yl)phenol; - 1 - { [4-(3,5-di½rr-butyl-4-hydroxyphenyl)- 1 ,3-thiazol-2-yl]methyl } piped din-4-ol; - 4-methylpentyl 2-[4-(l,l '-biphenyl-4-yl)-lH-iniidazol-2-yl]ethylcarbamate; - 3,3-dimethylbutyl 2-[4-(4-pyrrolidin-l-ylphenyl)-lH-imidazol-2-yl]ethylcarbamate; - isopentyl 2-[4-(l, -biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - hexyl 2-[4-(4'-bromo-l, r-biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - benzyl 2-[4-(4-rerr-butylphenyl)-lH-imidazol-2-yl]ethylcarbamate; - 3,3-dimethylbutyl 2-[4-( l,r-biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - hexyl 2-[4-(4-pyrrolidin-l-ylphenyl)-lH-imidazol-2-yl]ethylcarbamate; - hexyl 2-[4-(3,5-di½rt-butyl-4-hydroxyphenyl)-lH-imidazol-2-yl]ethylcarbamate; - 3,3-dimethylbutyl 2-[4-(3,5-di/m-butyl-4-hydroxyphenyl)-lH-imidazol-2-yl]ethylcarbamate; - 3,3-dimethylbutyl 2-[4-(4-methoxyphenyl)-lH-imidazol-2-yl]ethylcarbamate; - benzyl 2-[4-(3,5-dit 6. Use of one of the following compounds: - 2,6-di½rr-butyl-4-{ 2-[2-(methylamino)ethyl]-l,3-thiazol-4-yl}phenol; - 2,6-difm-butyl-4-[4-(hydroxymethyl)-l ,3-oxazol-2-yl]phenol; - 2,6-di ert-butyl-4- { 2-[ 1 -(methylamino)ethyl]- 1 ,3-thiazol-4-yl Jphenol; - 2,6-di/err-butyl-4-[2-(methoxymethyl)-l ,3-thiazol-4-yl]phenol; - 2,6-di/err-butyl-4- { 4-[(methylamino)methyl]- 1 ,3-oxazol-2-yl Jphenol; - N-{ [4-(3,5-dire/V-butyl-4-hydroxyphenyl)-l,3-thiazol-2-yl]methyl }acetamide; - ethyl [4-(3,5-di er/-butyl-4-hydroxyphenyl)-l,3-thiazol-2-yl]methylcarbamate; - 2,6-di/er butyl-4-[2-(mo holin-4-ylmethyl)-l ,3-thiazol-4-yl]phenol; - 2,6-di½rr-butyl-4-[2-(thiomo holin-4-ylmethyl)-l,3-thiazol-4-yl]phenol; - 4-[2-(anilinomethyl)-l ,3-thiazol-4-yl]-2,6-diterf-butylphenol; - 2,6-dirm-butyl-4-(2-{ [[2-(dimethylamino)ethyl](methyl)amino]methyl }-l ,3-thiazol-4-yl)phenol; - 2,6-ditert-butyl-4-{5-methyl-2-[(methylamino)methyl]-l ,3-thiazol-4-yl }phenol; - 1 -[4-( 10H-phenothiazin-2-yl)- 1 ,3-thiazol-2-yl]methanamine; - N-{ [4-(3,5-direr/-butyl-4-hydroxyphenyl)-l,3-thiazol-2-yl]methyl }-N-methy lacetami de ; - l -[4-(3,5-di½^butyl-4-methoxyphenyl)-l,3-thiazol-2-yl]-N-methylmethanamine; - 2,6-dirm-butyl-4-{ 2-[(ethylamino)methyl]-l ,3-thiazol-4-yl Jphenol; - 2,6-di½r/-butyl-4-{ 2-[(4-phenylpiperazin-l-yl)methyl]-l,3-thiazol-4-yl}phenol; - 2,6-di½rt-butyl-4-{2-[(4-methyl-l,4 -diazepan-l-yl)methyl]-l ,3-thiazol-4-yl Jphenol; - N- { 1 -[4-(4-anilinophenyl)- 1 ,3-thiazol-2-yl]ethyl } -N-methylamine; - 2,6-di/ 7. Use according to claim 6, characterized in that the compound used is chosen from one of the following compounds: - 2,6-di½/Y-butyl-4- { 2-[ 1 -(methylamino)ethyl] - 1 ,3-thiazol-4-yl }phenol ; - l -[4-(3,5-ditert-butyl-4-methoxyphenyl)-l,3-thiazol-2-yl]-N-methylmethanamine; - 2,6-di½r/-butyl-4-{ 2-[(ethylamino)methyl]-l,3-thiazol-4-yl Jphenol; - l-{ [4-(3,5-ditert-butyl-4-hydroxyphenyl)-l,3-thiazol-2-yl]methyl }piperidin-4-ol; - l-{ [4-(3,5-di-ier/-butyl-4-hydroxyphenyl)-l,3-thiazol-2-yl]methyl }pyrrolidin-3-ol; - l-{ [4-(3,5-di-reri-butyl-4-hydroxyphenyl)-l,3-thiazol-2-yl]methyl}azetidin-3-ol; - (3R)-l-{ [4-(3,5-di-tert-butyl-4-hydroxyphenyl)-l ,3-thiazol-2-yl]methyl}pyrrolidin-3-ol; - (35)-l-{ [4-(3,5-di-tert-butyl-4-hydroxyphenyl)-l ,3-thiazol-2-yl]methyl}pyrrolidin- 3- ol; - N, 2-dimethyl- 1 -[4-( 10H-phenothiazin-2-yl)- 1 ,3-thiazol-2-yl]propan- 1 -amine; and the pharmaceutically acceptable salts of the latter. 8. Use according to claim 6 or 7, characterized in that the medicament prepared is intended to treat one of the following disorders or diseases: Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, schizophrenia, depression and psychoses. 9. Use of one of the following compounds - 2,6-di rr-butyl-4- { 2-[2-(methylamino)ethyl]- 1 ,3-thiazol-4-yl Jphenol; - 2,6-dirm-butyl-4- { 2-[ 1 -(methylamino)ethyl]- 1 ,3-thiazol-4-yl Jphenol; - 2,6-direrr-butyl-4-{4-[(methylamino)methyl]-l,3-oxazol-2-yl}phenol; - 2,6-diiert-butyl-4-{5-methyl-2-[(methylamino)methyl]-l,3-thiazol-4-yl Jphenol; - l-[4-(3,5-diie^butyl-4-methoxyphenyl)-l,3-thiazol-2-yl]-N-methylmethanamine; - 2,6-ditm-butyl-4-{ 2-[(ethylamino)methyl]-l,3-thiazol-4-yl Jphenol; - 4-methylpentyl 2-[4-( 1 , 1 '-biphenyl-4-yl)- 1 H-imidazol-2-yl]ethylcarbamate; - 3,3-dimethylbutyl 2-[4-(4-pyrrolidin- 1 -ylphenyl)- 1 H-imidazol-2-yl]ethylcarbamate; - isopentyl 2-[4-(l , -biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - hexyl 2-[4-(4'-bromo-l, -biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbarnate; - benzyl 2-[4-(4-tert-butylphenyl)- lH-imidazol-2-yl]ethylcarbamate; - 3,3-dimethylbutyl 2-[4-( 1 , 1 -biphenyl-4-yl)- lH-imidazol-2-yl]ethylcarbamate; - hexyl 2-[4-(4-pyrrolidin-l -ylphenyl)- lH-imidazol-2-yl]ethylcarbamate; - hexyl 2-[4-(3,5-dite;v-butyl-4-hydroxyphenyl)-lH-imidazol-2-yl]ethylcarbamate; - hexyl 2-[4-(3,5-di½rt-butyl-4-hydroxyphenyl)-lH-imidazol-2-yl]ethylcarbamate; - 3,3-dimethylbutyl 2-[4-(4-methoxyphenyl)-lH-imidazol-2-yl]ethylcarbamate; - benzyl 2-[4-(3,5-di/e^butyl-4-hydroxyphenyl)-lH-imidazol-2-yl]ethylcarbamate; - benzyl 2-[4-(4-pyrrolidin-l-ylphenyl)-lH-imidazol-2-yl]ethylcarbamate; - 2-phenylethyl 2-[4-(l , -biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(4'-fluoro- 1 , 1 -biphenyl-4-yl)- lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(l,l '-biphenyl-4-yl)-5-methyl-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(4'-methyl- 1 , 1 '-biphenyl-4-yl)- lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(4'-chloro-l ,r-biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(2'-fluoro-l, r-biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(2', 4'-difluoro-l , r-biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(3'-chloro- 1 , 1 '-biphenyl-4-yl)- 1 H-imidazol-2-yl]ethylcarbamate; - butyl 2- [4-(3'-fluoro- 1 , 1 '-biphenyl-4-yl)- 1 H-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(4-isobutylphenyl)-lH-imidazol-2-yl]ethylcarbamate; - benzyl 2-[4-(4-isobutylphenyl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(3'-chloro-4'-fluoro-l, -biphenyl-4-yl)-lH-irrddazol-2-yl]ethylcarbarnate; - butyl 2-[4-(3', 4'-dichloro-l,r-biphenyl-4-yl)-lH-irnidazol-2-yl]ethylcarbamate; - butyl 2-[4-(4-propylphenyl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(4-ethylphenyl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(4'-cyano-l,r-biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(l, -biphenyl-4-yl)-5-ethyl-lH-imidazol-2-yl]ethylcarbarnate; - butyl 2-[4-(2'-chloro- 1 , 1 -biphenyl-4-yl)- lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(2', 3'-difluoro-l ,l '-biphenyl-4-yl)-lH-irnidazol-2-yl]ethylcarbarnate; - butyl 2-[4-(2'-bromo-l ,1 ,-biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(3', 5'-difluoro-l, -biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbarnate; - butyl 2-[4-(2'-methoxy- 1 , 1 '-biphenyl-4-yl)- lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(3'-nitro-l, -biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbarnate; - butyl 2-[4-(2', 5'-difluoro-l,r-biphenyl-4-yl)-lH-imidazol-2-yl]ethylcarbamate; - butyl 2-[4-(3'-methoxy- 1 , 1 '-biphenyl-4-yl)- lH-imidazol-2-yl]ethylcarbamate; or of a pharmaceutically acceptable salt of one of the latter for preparing a medicament intended to modulate the sodium channels. 10. Use according to claim 9, characterized in that the medicament prepared is intended to treat one of the following disorders or diseases: Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, migraine or pain and in particular neuropathic pain. For ftfae ApplloQR¾o Mmm com moie
IL158121A 2001-04-10 2003-09-25 5-membered heterocycles, pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments IL158121A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0104943A FR2823208B1 (en) 2001-04-10 2001-04-10 5-CHAIN CHAIN HETEROCYCLE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
FR0201811 2002-02-14
PCT/FR2002/001218 WO2002083656A2 (en) 2001-04-10 2002-04-09 5-membered heterocycles, preparation and use thereof as mao inhibitors and lipid peroxidation inhibitors, preparation thereof and use thereof as medicaments

Publications (1)

Publication Number Publication Date
IL158121A true IL158121A (en) 2010-04-15

Family

ID=26212970

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15812102A IL158121A0 (en) 2001-04-10 2002-04-09 5-membered heterocycles, preparation and application thereof as medicaments
IL158121A IL158121A (en) 2001-04-10 2003-09-25 5-membered heterocycles, pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL15812102A IL158121A0 (en) 2001-04-10 2002-04-09 5-membered heterocycles, preparation and application thereof as medicaments

Country Status (23)

Country Link
EP (1) EP1379514B1 (en)
JP (1) JP4422964B2 (en)
KR (1) KR100865809B1 (en)
CN (1) CN1284777C (en)
AR (1) AR036329A1 (en)
AU (1) AU2002307980B2 (en)
BR (2) BRPI0208703B1 (en)
CA (1) CA2443403C (en)
CZ (1) CZ304550B6 (en)
DE (1) DE60232959D1 (en)
ES (1) ES2328467T3 (en)
HK (1) HK1070055A1 (en)
HU (1) HU228192B1 (en)
IL (2) IL158121A0 (en)
IS (1) IS2724B (en)
MX (1) MXPA03009194A (en)
MY (1) MY142094A (en)
NO (1) NO326051B1 (en)
NZ (1) NZ528645A (en)
PL (1) PL211939B1 (en)
RU (1) RU2288224C2 (en)
TW (1) TWI248438B (en)
WO (1) WO2002083656A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI283577B (en) 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
WO2003048140A1 (en) 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
TW200500362A (en) * 2003-04-09 2005-01-01 Japan Tobacco Inc 5-membered heteroaromatic ring compound and pharmaceutical use thereof
DE60307049T2 (en) * 2003-04-25 2007-02-08 Neuro3D Use of piperazine phenothiazine derivatives for the manufacture of a medicament having neuroprotective and / or neurotropic effects on the CNS and / or PNS
FR2888116A1 (en) * 2005-07-08 2007-01-12 Sod Conseils Rech Applic THIAZOLE DERIVATIVES FOR TREATING DYSKINESIES
EP1806819A1 (en) * 2006-01-05 2007-07-11 Constructions Electroniques + Telecommunications, en abrégé "C.E.+T" Backup power system
TW200848417A (en) * 2007-02-22 2008-12-16 Organon Nv Indole derivatives
EP2771335A2 (en) * 2011-10-26 2014-09-03 Pfizer Limited (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
CN113831360A (en) * 2021-09-10 2021-12-24 中钢集团南京新材料研究院有限公司 Method for synthesizing 1-carbazole-boronic acid pinacol ester through amide ortho-oriented boronation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326770A (en) 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
AU4368996A (en) * 1994-11-23 1996-06-17 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US5969146A (en) * 1995-10-11 1999-10-19 Synthelabo Oxazolidin-2-one derivatives, preparation method therefor and therapeutical use thereof
EP0946587A2 (en) * 1996-12-16 1999-10-06 Fujisawa Pharmaceutical Co., Ltd. New amide compounds
FR2764889B1 (en) * 1997-06-20 2000-09-01 Sod Conseils Rech Applic NOVEL 2- (IMINOMETHYL) AMINO-PHENYL DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ID24564A (en) * 1997-10-06 2000-07-27 Lilly Co Eli NEW COMPOUNDS USING AS NERVOUS PROTECTION MATERIALS
ATE229954T1 (en) * 1998-06-12 2003-01-15 Sod Conseils Rech Applic BETACARBOLINE COMPOUNDS
AR023171A1 (en) * 1999-03-26 2002-09-04 Cocensys Inc PIRAZOLES, IMIDAZOLES, OXAZOLES, TIAZOLES, AND PIRROLES REPLACED BY ARILO, AND THE USE OF THEMSELVES.
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof

Also Published As

Publication number Publication date
WO2002083656A3 (en) 2003-01-03
CA2443403C (en) 2011-09-20
AR036329A1 (en) 2004-09-01
CN1284777C (en) 2006-11-15
HUP0303799A2 (en) 2004-03-01
NO20034524L (en) 2003-10-29
CN1535267A (en) 2004-10-06
JP4422964B2 (en) 2010-03-03
EP1379514A2 (en) 2004-01-14
CZ20033054A3 (en) 2004-05-12
IL158121A0 (en) 2004-03-28
BR0208703A (en) 2006-02-21
HK1070055A1 (en) 2005-06-10
KR100865809B1 (en) 2008-10-28
NO20034524D0 (en) 2003-10-09
MXPA03009194A (en) 2004-02-17
RU2003132471A (en) 2005-01-27
IS6979A (en) 2003-10-08
DE60232959D1 (en) 2009-08-27
TWI248438B (en) 2006-02-01
NZ528645A (en) 2004-11-26
RU2288224C2 (en) 2006-11-27
EP1379514B1 (en) 2009-07-15
PL211939B1 (en) 2012-07-31
PL372297A1 (en) 2005-07-11
MY142094A (en) 2010-09-15
JP2004531526A (en) 2004-10-14
BRPI0208703B1 (en) 2017-12-12
CZ304550B6 (en) 2014-07-02
AU2002307980B2 (en) 2007-06-21
HUP0303799A3 (en) 2008-03-28
HU228192B1 (en) 2013-01-28
KR20030094333A (en) 2003-12-11
IS2724B (en) 2011-03-15
CA2443403A1 (en) 2002-10-24
WO2002083656A2 (en) 2002-10-24
NO326051B1 (en) 2008-09-08
ES2328467T3 (en) 2009-11-13

Similar Documents

Publication Publication Date Title
IL158121A (en) 5-membered heterocycles, pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments
CA2226039A1 (en) Pyridylfuran and pyridylthiophene compounds
WO2002016381A3 (en) Composition and method for inhibiting platelet aggregation
WO2002085901A8 (en) Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor agonists)
CA2246839A1 (en) Pharmaceutical compositions containing ampa receptor antagonists for treating dyskineslas associated with dopamine agonist therapy
SG45259A1 (en) New thiazolybenzofuran derivatives processes for the preparation thereof and pharmaceutical composition comprising the same
IL137266A0 (en) Heterocyclic chemokine receptor antagonists and pharmaceutical compositions containing the same
SK112001A3 (en) Agents with an antidepressive effect containing pramipexol and an additional antidepressant drug
ZA200606870B (en) Oxadiazolone derivatives as PPAR delta agonists
EP1996546A2 (en) Substituted gamma lactams as prostaglandin ep2 agonists
EP1372657A2 (en) A method of treating proliferative diseases using eg5 inhibitors
TW340115B (en) Triazine derivatives and pharmaceutical composition for hepatitis the invention relates to triazine derivatives and pharmaceutical composition for hepatitis
NZ320355A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
JP2004516295A5 (en)
IE912602A1 (en) Use of heterocyclic amino-alcohol compounds for treatment of CNS diseases
JP2003514893A5 (en)
IL124673A0 (en) Heterobicyclic derivatives a process for their preparation use thereof and pharmaceutical compositions containing the same
TR199701497T1 (en) Composition that prevents brain disease.
WO2010020610A1 (en) Compounds for the treatment of peripheral neuropathies
MX2008014921A (en) Substituted pyrazinone derivatives for use as a medicine.
BR0009897A (en) Pharmaceutical
BR0009898A (en) Pharmaceutical
GR3032038T3 (en) N-Benzyl-Indoles, processes for their preparation and pharmaceutical compositions containing them.
AU3459395A (en) New 5-(aryloxymethyl)oxazolines, a process for the preparation thereof and pharmaceutical compositions containing them
CA2579756A1 (en) Modulators of central nervous system neurotransmitters

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees